Table 1 Phase 3 vaccine efficacy data of Arexvy® and Abrysvo® and the efficacy values of an RSV hypothetical vaccine
Arexvy® (GSK) | Abrysvo® (Pfizer) | ||||
|---|---|---|---|---|---|
Endpoints | Season 1 (full season) | Season 2 (full season) | Endpoints | Season 1 (full season) | Season 2 (full season) |
ARI ≥1 symptom | 62.1% (95% CI 37.1–77.9) | Not shared in public domain yet | |||
ARI ≥2 symptoms or sign | 71.7% (95% CI 56.2–82.3) | 40.6% (95% CI 19.0–57.0) | |||
LRTD ≥2 symptoms including ≥1 sign or ≥3 symptoms | 82.6% (96.95% CI 57.9–94.1) | 56.1% (95% CI 28.2–74.4) | LRTD ≥2 symptoms or signs | 66.7% (96.66% CI 28.8–85.8) | 55.7% (95% CI 34.7–70.4) |
LRTD ≥3 symptoms or signs | 85.7% (96.66% CI 32.0–98.7) | 77.8% (95% CI 51.4–91.1) | |||
Severe LRTD (≥2 signs or defined as severe by investigator) | 94.1% (95% CI 62.4–99.9) | 64.2% (95% CI 61.6–93.4%) | |||
RSV hypothetical vaccine | |||||
Vaccine efficacy against | Season 1 (full season) | Season 2 (full season) | |||
Non-MA | 65% (35–85%) | 35% (15–60%) | |||
Primary care | 65% (35–85%) | 35% (15–60%) | |||
Hospitalisation | 80% (35–95%) | 55% (25–80%) | |||
Death | 90% (60–100%) | 60% (55–95%) | |||